Patents Assigned to IDOGEN AB
  • PSAMMAPLIN A FOR MODULATING IDO EXPRESSION
    Publication number: 20210299069
    Abstract: The present invention relates to ex vivo methods using psammaplin A, the compound of formula (I) and related uses.
    Type: Application
    Filed: August 25, 2017
    Publication date: September 30, 2021
    Applicant: IDOGEN AB
    Inventors: Peter ERICSSON, Hans Olov SJÖGREN
  • EX VIVO METHODS OF INDUCING IDO EXPRESSION IN ANTIGEN PRESENTING CELLS USING A COMPOUND SELECTED FROM THE GROUP CONSISTING OF AZACYTIDINE, AND DECITABINE
    Publication number: 20190201431
    Abstract: The present invention relates to ex vivo methods using a compound selected from the group consisting of azacytidine, a compound of formula (I): and decitabine, a compound of formula (II): and related uses of said compounds.
    Type: Application
    Filed: August 25, 2017
    Publication date: July 4, 2019
    Applicant: IDOGEN AB
    Inventors: Peter ERICSSON, Hans Olov SJÖGREN
  • NOVEL USE
    Publication number: 20190192543
    Abstract: The present invention relates to ex vivo methods using guadecitabine, the compound of formula (I) and related uses.
    Type: Application
    Filed: August 25, 2017
    Publication date: June 27, 2019
    Applicant: IDOGEN AB
    Inventors: Peter ERICSSON, Hans Olov SJÖGREN
  • Methods of inducing indolamine 2,3—dioxygenase (IDO)
    Patent number: 9839674
    Abstract: A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: December 12, 2017
    Assignee: Idogen AB
    Inventors: Leif Salford, Hans Olov Sjogren, Bengt Widegren
  • COMPOSITION COMPRISING AT LEAST TO COMPOUNDS WHICH INDUCES INDOLAMINE 2,3 - DIOXYGENASE (IDO), FOR THE TREATMENT OF AN AUTOIMMUNE DISORDER OR SUFFERING FROM IMMUNE REJECTION OF ORGANS
    Publication number: 20130309198
    Abstract: A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine 2,3-dioxygenase, for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the inducers have different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.
    Type: Application
    Filed: December 20, 2011
    Publication date: November 21, 2013
    Applicant: IDOGEN AB
    Inventors: Leif Salford, Hans Olov Sjogren, Bengt Widegren